CureTech (Pidilizumab Drug) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
CureTech (Pidilizumab Drug) General Information
Description
Humanized monoclonal antibody (mAb). The drug modulates the immune response and inhibits tumor growth and the spread of metastases. It binds the PD-1 protein on T lymphocytes and facilitates the T-cells' ability to target and destroy cancer cells.
Contact Information
Corporate Office
- 42 Hayarkon Street
- Yavne 81227
- Israel
Corporate Office
- 42 Hayarkon Street
- Yavne 81227
- Israel
CureTech (Pidilizumab Drug) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CureTech (Pidilizumab Drug) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CureTech (Pidilizumab Drug) FAQs
-
Where is CureTech (Pidilizumab Drug) headquartered?
CureTech (Pidilizumab Drug) is headquartered in Yavne, Israel.
-
What industry is CureTech (Pidilizumab Drug) in?
CureTech (Pidilizumab Drug)’s primary industry is Buildings and Property.
-
Is CureTech (Pidilizumab Drug) a private or public company?
CureTech (Pidilizumab Drug) is a Private company.
-
What is CureTech (Pidilizumab Drug)’s current revenue?
The current revenue for CureTech (Pidilizumab Drug) is .
-
Who are CureTech (Pidilizumab Drug)’s investors?
Clal Industries and CureTech have invested in CureTech (Pidilizumab Drug).
-
When was CureTech (Pidilizumab Drug) acquired?
CureTech (Pidilizumab Drug) was acquired on 23-Oct-2014.
-
Who acquired CureTech (Pidilizumab Drug)?
CureTech (Pidilizumab Drug) was acquired by Medivation (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process